A retrospective study of Yiqi-Huoxue Decoction on blood pressure in patients with acute ischemic stroke

Chao Jiang, MD^a,b, Ting Wang, MD^c, Yong-Cheng Xu, MM^d, Ying Gao, MM^e, Bang-Jiang Fang, MD^b,∗

Abstract
This retrospective study investigated the effect of Yiqi-Huoxue Decoction (YQHXD) on blood pressure (BP) in patients with acute ischemic stroke (AIS).

A total of 72 patients with BP following AIS who received routine treatment were included in this retrospective study. Of those, 36 patients received YQHXD and were assigned to a treatment group. The other 36 patients were allocated to a control group. All patients were treated for a total of 4 months. The outcomes were assessed by systolic blood pressure (SBP), diastolic blood pressure (DBP), National Institutes of Health Stroke Scale (NIHSS) score and Barthel index scale (BIS). All outcomes were measured after 4-month treatment.

After treatment, all subjects in the treatment group showed greater improvements in SBP (P < .05), DBP (P < .05), NIHSS (P < .05) score, and BIS (P < .05) than those of patients in the control group. In addition, the safety profile is similar in both groups.

The findings of this study demonstrated that YQHXD may benefit on BP in patients with AIS. Future studies should focus on warranting the current results.

Abbreviations: AIS = acute ischemic stroke, BP = blood pressure, BIS = Barthel index scale, DBP = diastolic blood pressure, NIHSS = National Institutes of Health Stroke Scale, SBP = systolic blood pressure, YQHXD = Yiqi-Huoxue Decoction.

Keywords: acute ischemic stroke, Yiqihuoxue Formula, blood pressure, effect

1. Introduction
Acute ischemic stroke (AIS) is a very common acute cerebrovascular event resulted from decreased blood flow to the brain.[1,2] It is also the leading cause of high mortality and morbidity.[3,4] It is estimated that about 13 million cases occur annually worldwide.[4] Study reports that about 13 million people in China, and its mortality rate is about 1.15/1000 people around the world.[7] A variety of risk factors and plasma neuroendocrine biomarkers are associated with AIS, such as high blood pressure (BP), diabetes, heart and blood vessel diseases, high low-density lipoproteins, smoking, brain aneurysms, age, gender, race and ethnicity, family history and genetics.[8-11] Of those, BP is the most important risk factor for AIS.[10,11]

Antihypertensive treatments are very important to manage patients with such condition.[12] Of those, Yiqi-Huoxue Decoction (YQHXD), a type of Chinese herbal medicine, has been...
widely used for a variety of diseases, including spinal cord injury, ischemic stroke, diabetic nephropathy, coronary heart disease, acute cerebral infarction, superficial thrombophlebitis, thoracic obstruction, and ischemic stroke.\textsuperscript{18–23} It is tailored for AIS survivors, who are also featured with BP.\textsuperscript{24,30} Its mechanism is obstruction, and ischemic stroke.\textsuperscript{18}

2. Patients and methods

2.1. Ethical consideration

The ethical approval of this study was approved by the Ethics Medical Committee of Longhua Hospital Shanghai University of Traditional Chinese Medicine. The written informed consent of all patients is available.

2.2. Study design

This study included a total of 72 patients with AIS, and all of them were performed at Longhua Hospital Shanghai University of Traditional Chinese Medicine between March 2017 and December 2018. All patients in both groups received routine treatment for a total of 4 months. Of those, 36 patients who received YQHXD were assigned to the treatment group, while the other 36 patients who did not administrate YQHXD were assigned to the control group. All outcomes were measured after 4 months treatment. We employed blind approach to data analyst in this study. However, we did not use randomization and concealment allocation to patients and investigators, because this is a retrospective study and all data were collected from completed case records.

2.3. Patients

We included patients if they fulfilled all inclusion criteria:

(1) diagnosed as hypertension based on the Revised Guidelines for Prevention and Treatment of Hypertension in China,\textsuperscript{31} and AIS according to the Chinese Cerebrovascular Disease Prevention and Treatment Guideline\textsuperscript{32};
(2) age between 20 and 75 years old;
(3) blood pressure (BP) $\geq 140/90$ mm Hg, systolic BP (SBP) $\geq 140$ mm Hg or diastolic BP (DBP) $\geq 90$ mm Hg; and
(4) provided written informed consent.

The exclusion criteria were as follows:

(1) pregnant or lactation;
(2) cerebral hemorrhage;
(3) severe or critical organ diseases, such as heart failure, and cancers;
(4) BP $< 140/90$ mm Hg, SBP $< 130$ mm Hg or DBP $< 90$ mm Hg;
(5) incomplete patient information; and
(6) written informed consent was not provided.

2.4. Treatment approach

All patients with hypertension following AIS in both groups received routine treatment according to the Revised Guidelines for Prevention and Treatment of Hypertension in China\textsuperscript{31} and Chinese Cerebrovascular Disease Prevention and Treatment Guideline.\textsuperscript{32} Additionally, patients in the treatment group administrated YQHXD. It comprises of Astragalus 60g, Angelica tail 15g, Chuanxiong Rhizome 12g, Red Peony Root 12g, Geosaurus 20g, Peach Kernel 6g, Safflower 6g, Salvia Miltiorrhiza 12g, Heliotrope 12g, and Cinnamonomum Cassia Presl 6g. All patients administered orally twice daily at morning and evening before meals for a total of 4 months.

2.5. Outcome measurements

Primary outcomes were changes of SBP and DBP.\textsuperscript{33–36} Secondary outcomes were National Institutes of Health Stroke Scale (NIHSS),\textsuperscript{37} Barthel index scale (BIS),\textsuperscript{38} and adverse events. NIHSS is utilized to objectively appraise neurological impairment for stroke survivors.\textsuperscript{37} Its total score ranges from 0 to 42, with higher score indicating poorer dysfunction.\textsuperscript{37} BIS score is used to assess quality of daily life in stroke survivors.\textsuperscript{16} Its total score varies from 0 to 100, with lower score meaning poorer disability.\textsuperscript{38} In addition, we also analyzed adverse events in both groups. All outcomes were analyzed after 4-month treatment.

2.6. Statistical analysis

This study employed SAS package (Version 9.1; SAS Institute Inc., Cary, NC) to statistically analyze all baseline data and outcome values. We analyzed all continuous values using Mann-Whitney U test or t test, and all categorical values using Chi-square test or Fisher exact test. We defined a 2-side value of $P < .05$ as a statistical significance. Considering no study specifically addresses the effects of YQHXD on BP in patients with AIS, the minimum number of patients necessary to appraise

| Characteristics | Treatment group (n = 36) | Control group (n = 36) | P |
|-----------------|-------------------------|------------------------|---|
| Age (yr)        | 64.5 (9.1)              | 66.7 (10.0)            | .33|
| Gender          |                         |                        |    |
| Males           | 17 (47.2)               | 21 (58.3)              | .35|
| Females         | 19 (52.8)               | 15 (41.7)              | .35|
| Race (Chinese Han) | 36 (100.0)         | 36 (100.0)             | -  |
| BMI (kg/m\textsuperscript{2}) | 23.8 (2.2)         | 23.1 (2.5)              | .21|
| Duration of post stroke (month) | 3.2 (2.4)          | 3.6 (2.1)              | .45|
| Duration of BP (yr) | 38.7 (11.2)        | 34.5 (13.1)             | .14|
| Co-morbidities |                         |                        |    |
| Hypertension    | 36 (100.0)              | 36 (100.0)             | –  |
| High cholesterol| 16 (44.4)               | 14 (38.9)              | .63|
| Diabetes        | 11 (30.6)               | 13 (36.1)              | .62|
| Heart disease   | 7 (19.4)                | 9 (25.0)               | .57|
| Angina          | 8 (22.2)                | 6 (16.7)               | .55|
| Heart attack    | 5 (13.9)                | 3 (8.3)                | .46|
| Current smoking | 15 (41.7)               | 17 (47.2)              | .64|
| Other           | 6 (16.7)                | 7 (19.4)               | .76|
| SBP (mm Hg)     | 155.5 (6.8)             | 157.2 (7.3)            | .31|
| DBP (mm Hg)     | 95.3 (4.4)              | 96.1 (3.9)             | .41|
| NIHSS           | 11.7 (2.1)              | 12.1 (2.4)             | .45|
| BIS             | 65.9 (18.0)             | 62.5 (16.3)            | .40|

Data are present as mean$\pm$standard deviation or number (%). BMI = body mass index, BIS = Barthel index scale, BP = blood pressure, DBP = diastolic blood pressure, NIHSS = National Institute of Health Stroke Scale, SBP = systolic blood pressure.
DBP (mm Hg) from baseline).

| BP (mm Hg) | Treatment group (n=36) | Control group (n=36) | P |
|------------|------------------------|----------------------|---|
| SBP (mm Hg) | -13.4 (16.9, -9.7)     | -7.2 (-10.1, -4.0)  |   |
| DBP (mm Hg) | -5.8 (-7.3, 4.3)       | -3.2 (-4.3, -2.0)   |   |

Data are present as mean (range). NP = systolic BP, SBP = diastolic BP.

Table 3: Comparison of NIHSS after treatment between 2 groups.

| NIHSS | Treatment group (n=36) | Control group (n=36) | P |
|-------|------------------------|----------------------|---|
| Change from baseline | -7.1 (-8.6, -5.4) | -5.3 (-6.5, -4.0) |   |
| Difference between 2 groups | -1.7 (-2.4, -1.1) | <.05 |

Data are present as mean (range); NIHSS, National Institute of Health Stroke Scale.

its effects with a total sample size of 72 patients, including assumption of 20% dropout rate,[39] each group 36 patients.

3. Results

We summarized general characteristics and demographic values of all patients in both groups in Table 1. We compared all those characteristics and demographics in patients between two groups. There are not significant statistical differences regarding those data between two groups (Table 1).

After 4-month treatment, patients in the treatment group showed better outcomes in primary outcome measurements of SBP (P < .05, Table 2) and DBP (P < .05, Table 2), and secondary outcome measurements of NIHSS (P < .05, Table 3), and BIS (P < .05, Table 4), than those of patients in the control group. No treatment-related adverse events were reported in both groups after 4-month treatment.

4. Discussion

This retrospective study exerted promising outcomes of YQHXD on BP in AIS survivors after 4-month treatment. To our best knowledge, there is still insufficient available evidence to support the effects of YQHXD on BP management in patients with AIS. Thus, this retrospective study investigated the effects and safety of YQHXD on BP in AIS survivors.

Several studies reported the effects of YQHXD on BP management.[40–46] However, all of them assessed YQHXD on BP in other diseases, and no study specifically assessed the effects of YQHXD on BP in patients with stroke. In this study, our results showed promising effects of YQHXD on BP in AIS survivors.

The results of this study showed that patients in the treatment group exerted better outcomes of SBP (P < .05), DBP (P < .05), NIHSS (P < .05), and BIS (P < .05), than those of patients in the control group. It indicates that YQHXD may benefit BP in patients with AIS. In addition, both groups had similar safety profile.

There are several limitations in this retrospective study. First, this study has an intrinsic restriction. Second, this study did not apply randomization allocation and blinding to both patients and practitioners, which may result in high risk of selection. Third, this study only conducted at one center of Longhua Hospital Shanghai University of Traditional Chinese Medicine, which may affect its generalization to other hospitals. Fourth, the sample size of this study is pretty small, which impact its power. Finally, this study only measured outcomes after treatment, and no outcomes were measured at other time points. Thus, future studies should avoid those limitations.

5. Conclusion

The results of this study showed that YQHXD may be efficacious and safe for BP management in patients with AIS. Future high quality studies should warrant current findings.

Author contributions

Conceptualization: Chao Jiang, Yong-Cheng Xu, Ying Gao, Bang-Jiang Fang.
Data curation: Chao Jiang, Ting Wang, Ying Gao, Bang-Jiang Fang.
Formal analysis: Chao Jiang, Yong-Cheng Xu, Bang-Jiang Fang.
Investigation: Ying Gao, Bang-Jiang Fang.
Methodology: Yong-Cheng Xu, Ting Wang.
Project administration: Ying Gao, Bang-Jiang Fang.
Resources: Chao Jiang, Yong-Cheng Xu, Ting Wang, Ying Gao.
Software: Chao Jiang, Yong-Cheng Xu, Ting Wang.
Supervision: Ying Gao, Bang-Jiang Fang.
Validation: Chao Jiang, Yong-Cheng Xu, Ying Gao, Bang-Jiang Fang.
Visualization: Chao Jiang, Ting Wang, Ying Gao, Bang-Jiang Fang.
Writing – original draft: Yong-Cheng Xu, Ting Wang, Ying Gao, Bang-Jiang Fang.
Writing – review & editing: Chao Jiang, Yong-Cheng Xu, Ting Wang, Ying Gao, Bang-Jiang Fang.

References

[1] Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early Management of Patients with Acute Ischemic Stroke: 2019 update to the 2018 guidelines for the early Management of Acute Ischemic Stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2019;50:e344–518.
[2] Minematsu K. Acute ischemic stroke. Rinsho Shinkeigaku 2019;79(Suppl 2):1–56.
[3] Gattringer T, Posekany A, Niederkorn K, et al. Predicting early mortality of acute ischemic stroke. Stroke 2019;50:349–56.
[4] Pigretti SG, Alet MJ, Mamani CE, et al. Consensus on acute ischemic stroke. Medicina (B Aires) 2019;79(Suppl 2):1–46.
[5] Phipps MS, Cronin CA. Management of acute ischemic stroke. BMJ 2020;368:k6893.
[6] Feigin VL, Roth GA, Naghavi M, et al. Global burden of stroke and risk factors in 188 countries, during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet Neurol 2016;15:913–24.
[7] Wang W, Jiang B, Sun H, et al. Prevalence, incidence, and mortality of stroke in China: results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation 2017;135:759–71.
[8] Gurunadiharao . Lipoprotein(a) levels as an independent risk factor for ischemic stroke. J Assoc Physicians India 2020;66:62.
[9] Guzik A, Bushnell C. Stroke epidemiology and risk factor management. Continuum (Minneap Minn) 2017;23:13–39.
[10] Hörnsten C, Weidung B, Littbrand H, et al. High blood pressure as a risk factor for incident stroke among very old people: a population-based cohort study. J Hypertens 2016;34:2059–63.
[11] Nave AH, Lange KS, Leonards CO, et al. Lipoprotein (a) as a risk factor for ischemic stroke: a meta-analysis. Atherosclerosis 2015;242:496–503.
[12] Shou J, Zhou L, Zhu S, et al. Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis 2015;24:1961–8.
[13] Okkainen A, Engblom J, Kääriäinen M, et al. Risk factor-related lifestyle habits of hospital-admitted stroke patients-an exploratory study. J Clin Nurs 2015;24:2219–30.
[14] Sharma VK, Tan BYQ, Sim MY, et al. Rationale and design of a randomized trial of early intensive blood pressure lowering on cerebral perfusion parameters in thrombolysed acute ischemic stroke patients, Medicine (Baltimore) 2018;97:e12721.
[15] Tu WJ, Dong X, Zhao SJ, et al. Prognostic value of plasma neuroendocrine biomarkers in patients with acute ischemic stroke. J Neuroendocrinol 2013;25:771–8.
[16] Redon J, Olsen MH, Cooper RS, et al. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of blood high pressure. Eur Heart J 2011;32:1424–31.
[17] Ye Z, Ai X, Zheng J, et al. Antihypertensive treatments for spontaneous intracerebral hemorrhage in patients with thromboclooblastic fracture and incomplete spinal cord injury. J Neck and Waist pain 2020;41:461–3.
[18] Zhao YD. Application of acupuncture combined with Yiqi Huoxue decoction in late rehabilitation treatment of ischemic stroke patients. Clin Res Trad Chin Med 2020;12:52–4.
[19] Zhou L. Curative effect of Yiqi Huoxue decoction on early diabetic nephropathy patients with deficiency of both Qi and Yin. Henan Med Res 2020;29:2242–3.
[20] Tian R. Application value of Yiqi Huoxue decoction in treating thoracic obstruction due to Qi deficiency and blood stasis. Electro J Clin Med Lit 2017;4:3109–12.
[21] Zhang R, Song JP, Ji YH. The clinical study of Yiqi Huoxue decoction in the treatment of acute spinal cord injury. Pharmacol Clin Chin Mater Med 2015;31:128–31.
[22] Sun SG. Effect of Yiqi Huoxue decoction on neurologic function and hemorheology in patients with ischemic stroke. Shanxi Trad Chin Med 2013;36:808–9.
[23] Huang H, Tang Y, Wan S. Clinical observation on effect of yiqi huoxue decoction over the left ventricular diastolic dysfunction. Chin J Integr Med 1996 Feb;16:70–3.
[24] Tong CQ, Di Y, Liu ZQ, et al. Effect of yiqi huoxue recipe on cardiac function and ultrastructure in regression of pressure overload-induced myocardial hypertrophy in rats. Chin J Integr Med 2007;13:291–6.
[25] Revision Committee of Guidelines for Prevention and Treatment of Hypertension in China . Chinese Guidelines for Prevention and Treatment of Hypertension 2010 Revised Edition. Beijing: People’s Medical Publishing House; 2012. 25.
[26] Zhou L. Curative effect of Yiqi Huoxue decoction on early diabetic nephropathy patients with deficiency of both Qi and Yin. Electro J Clin Med Lit 2018;49:1836–42.
[27] Maier IL, Tsogkas I, Behme D, et al. High systolic blood pressure after successful endovascular treatment affects early functional outcome in acute ischemic stroke. Cerebrovasc Dis 2018;45:18–25.
[28] Caseo V, Agundis G, Albertis A, et al. High diastolic blood pressure is a risk factor for in-hospital mortality in complete MCA stroke patients. Neurology 2012;33:545–9.
[29] Microangiopathia H. Higher diastolic blood pressure at admission and antiedema therapy is associated with acute kidney injury in acute ischemic stroke patients. Int J Nephrol Renovasc Dis 2014;7:101–5.
[30] Mage Vu, The NIH stroke scale: a window into neurological status. Nurs Spectr 2011;24:44–9.
[31] Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969;9:179–86.
[32] Johanson GA, Brooks GP. Initial scale development: sample size for pilot studies. Educ Psychol Meas 2010;70:394–400.
[33] Wang C, Zhang LD, Gu LY, et al. Clinical observation on the treatment of “H-type” hypertension (Qi deficiency and blood stasis) in the elderly with Yiqi Huoxue Decoction. J Pract Tradit Chin Intern Med 2020;34:123–6.
[34] Zheng WH, Ruan SJ. Effect of Yiqi Huoxue Recipe on urinary microprotein/creatinine and blood pressure in patients with Qi deficiency and blood stasis hypertension. Med Equap 2018;31:16–8.
[35] Li Z, Xiao LY, Yu Q, et al. The clinical efficacy of Yiqi Huoxue Recipe on patients with chronic visceral diseases and hypertension. World Tradit Chin Med 2017;12:45–8.
[36] Li SL, Pan W, Kang KB, et al. Clinical observation on the treatment of elderly “H-type” hypertension (Qi Deficiency and Blood Stasis Syndrome) by Yiqi Huoxue Decoction. West J Tradit Chin Med 2017;30:62–5.
[37] Li SL, Liu GA, Ye BL. Clinical observation of 48 cases of “H-type” hypertension with Qi deficiency and blood stasis syndrome treated by Yiqi Huoxuefang combined with conventional antihypertensive western medicine. J Gansu Univ Tradit Chin Med 2016;33:72–6.
[38] Xu T. The effect of the traditional Chinese medicine prescription for replenishing qi and promoting blood circulation combined with western medicine on the symptom and blood pressure control of elderly hypertensive patients. Chin J Geront 2013;33:5121–2.